Cost-Effectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996)

Bethan George, Anthony Howard Harris and Andrew Mitchell
Additional contact information
Bethan George: Centre for Policy and Practice, University of London School of Pharmacy, Tower Hamlets PCG and Barts' and the London NHS Trust, London, UK
Andrew Mitchell: Pharmaceutical Evaluation Section, Department of Health and Aged Care, Canberra, Australia

PharmacoEconomics, 2001, vol. 19, issue 11, pages 1103-1109

Abstract: Objective: The principle aim of this study was to generate a league table of drugs considered by the Australian Pharmaceutical Benefits Advisory Committee (PBAC) for reimbursement. The table was used to test the hypothesis that decisions made by the PBAC are consistent with the maxim of economic efficiency. In addition, we explored whether the past decisions by the PBAC revealed a threshold incremental cost-effectiveness ratio beyond which the PBAC is not prepared to recommend reimbursement of a drug. Methods: All 355 submissions made to the PBAC between January 1991 and June 1996 were reviewed. Submissions using cost per life-year gained (26 submissions) or the cost per quality adjusted life-year (QALY) gained (9 submissions) were ranked in a league table and compared with advice given by the PBAC about that drug. The confidentiality restrictions for the submissions require that the individual drug details cannot be revealed in this article. Results: There was a statistically significant difference between the cost per life-year gained for drugs that were recommended for listing and those that were not, suggesting that the PBAC has been broadly consistent with the use of economic efficiency as a criterion for decision making. We did not find an explicit threshold beyond which the PBAC was unwilling to pay for additional life years gained. However, between 1992 and 1996 the PBAC appears to have been unlikely to recommend a drug for listing if the additional cost per life-year exceeded 76 000 Australian dollars [$AU] (1998/1999 values) and was unlikely to reject a drug for which the additional cost per life-year gained was less than $AU42 000. The cost-effectiveness ratio was not the only factor determining the reimbursement decision. Conclusions: The results of this preliminary study indicate that decisions to recommend a drug for listing by the PBAC in the last few years have, by and large, been consistent with the notion of economic efficiency.

Keywords: Cost effectiveness; Pharmacoeconomics; Reimbursement (search for similar items in EconPapers)
JEL-codes: C D I Z I1 I19 I18 I11 (search for similar items in EconPapers)
Date: 2001

Downloads: (external link)
http://pharmacoeconomics.adisonline.com/pt/re/phe/ ... -200119110-00004.pdf (application/pdf)
http://pharmacoeconomics.adisonline.com/pt/re/phe/ ... -200119110-00004.htm (text/html)
Pay per view

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: http://EconPapers.repec.org/RePEc:wkh:phecon:v:19:y:2001:i:11:p:1103-1109

Access Statistics for this article

PharmacoEconomics is edited by Christopher I. Carswell, MSc, MRPharmS

More articles in PharmacoEconomics from Wolters Kluwer Health | Adis
Series data maintained by Remco Bouckaert ().